ENOV

Enovis Corporation

Enovis Corporation (ENOV) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Growth (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B
Factor Score 3.3 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 8.0
EV / EBITDA 7.7
Rev Growth YoY 1.8%
Gross Margin 61.3%
Price Return 3M 14.3%
Price Return 12M 0.6%
Catalyst Signal 0.00
Market Cap $1.6B
TTM Revenue $2.3B
Price / Sales 0.7
ROE -30.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B (3.3) C- (1.9) B- (3.0) C+ (2.5) C+ (2.6) C+ (2.7)
2026-11-04 B (3.3) C- (1.9) B- (3.0) D+ (1.7) C+ (2.7) C+ (2.5)
2026-10-28 B (3.3) C- (1.9) B- (2.9) D+ (1.6) C+ (2.7) C (2.5)
2026-10-21 B (3.3) C- (1.9) B- (2.9) D+ (1.7) C+ (2.6) C (2.5)
2026-10-14 B (3.3) C- (1.9) B- (2.9) D+ (1.7) C+ (2.6) C (2.5)
Page 1 of 4